A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Nov 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how to better screen and follow up with individuals who are at high risk for pancreatic cancer, specifically a type called pancreatic ductal carcinoma (PDAC). The researchers will use a procedure called endoscopic ultrasound (EUS), along with other methods, to identify early signs of cancer in these individuals. They will also collect samples to look for specific markers in the body that could help in diagnosing pancreatic cancer earlier.

To participate, individuals aged 18 to 80 who have been admitted to certain hospitals and meet specific high-risk criteria may be eligible. These criteria include having a history of pancreatitis, a family history of pancreatic cancer, elevated tumor markers, certain types of pancreatic tumors, or being newly diagnosed with diabetes. Participants will undergo initial screening and follow-up tests, and their experiences will help improve future cancer detection. It's important to note that individuals who are not able to undergo certain medical examinations or who do not fully understand the study may not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • From the beginning of the study to the end of the study, the 18-80 year old patients who were admitted to Peking Union Medical College Hospital and related research centers and who met the high-risk population of pancreatic cancer understood and were willing to participate in the study and signed the informed consent form.
• * In this study, the high-risk population of pancreatic cancer is defined as patients who meet any of the following conditions:
• • A. Patients with previous history of pancreatitis (acute or chronic).
• • B. Patients with pancreatic cancer related genetic background, including immediate relatives with a family history of pancreatic cancer. Or genetic syndrome related to pancreatic cancer. \[including hereditary breast cancer ovarian cancer syndrome (HBOCS), carney complex (CNC), familial adenomatous polyps (FAP), hereditary diffuse gastric cancer syndrome (HDGC), juvenile polyposis (JPS), cutaneous malignant melanoma (CMM), hereditary papillary renal cell carcinoma (HPRCC) and Lynch syndrome\]
• • C. Patients with continuous or progressive increase of CA19-9 and CEA.
• • D. Patients with potential malignant pancreatic tumors, including mucinous cystic tumor (MCN) and intraductal papillary myxoma of the pancreas (IPMN).
• • E. Newly diagnosed patients with diabetes (within 3 years after diagnosis of diabetes).
• • F. Other patients who are considered as having high risk factors for pancreatic cancer.
• Exclusion Criteria:
• • A. Those who are not suitable for endoscopic examination, including but not limited to: poor general condition, serious heart and lung disease, and difficult to tolerate the examination; coagulation disorders; platelets \<50 × 10\^9/L；those who are not suitable for endoscopic examination after interview by an endoscopic physician.
• • B. The patient or family member could not understand the conditions and objectives of this study.